Renovorx Inc (RNXT)

$0.92 -0.04 (-3.67%)
Market Cap 41.45M
Revenue (ttm) 1.12M
Net Income (ttm) -11.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -997.32%
Debt to Equity Ratio 0.00
Volume 205,000
Avg Vol 288,602
Day's Range N/A - N/A
Shares Out 45.05M
Stochastic %K 37%
Beta 0.99
Analysts Strong Sell
Price Target $7.00

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
iAccess_Alpha
iAccess_Alpha Jul. 2 at 3:51 PM
Missed it live? Access the $RNXT presentation replay here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
Wolfietrader
Wolfietrader Jun. 30 at 8:05 PM
$RNXT I bought 1,400 more shares. Why do I do this? Why? I like pain and mental suffering I guess
1 · Reply
Wolfietrader
Wolfietrader Jun. 30 at 3:12 PM
$RNXT so close to the Mendoza line.
1 · Reply
Wolfietrader
Wolfietrader Jun. 26 at 3:25 PM
$RNXT strange upward movement. I’m not familiar with this. Next thing you know the stock will be at $1.00. Strange days.
1 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 25 at 2:58 PM
$RNXT presentation replay now available. Access here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 24 at 4:26 PM
$RNXT wtf is that???
3 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 24 at 1:34 PM
$RNXT let’s get one hundredth of a cent gain today boys!
1 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 23 at 12:35 PM
$RNXT presents today at iAccess Alpha's Virtual Best Ideas Summer Conference. Watch live via Stocktwits or register here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 22 at 2:17 PM
$RNXT presents tomorrow at iAccess Alpha's Virtual Best Ideas Summer Conference. Watch live: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
KirkHanna
KirkHanna Jun. 17 at 6:21 PM
$RNXT Not bad price action, considering there's no catalyst next several weeks. I wonder if institutional investors have noticed it?
1 · Reply
Latest News on RNXT
RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026

Jun 23, 2026, 12:30 PM EDT - 11 days ago

RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026

RenovoRx Slides: Investor presentation

Jun 15, 2026, 7:00 AM EDT - 19 days ago

RenovoRx Slides: Investor presentation

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Jun 11, 2026, 8:30 AM EDT - 23 days ago

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Jun 4, 2026, 8:30 AM EDT - 4 weeks ago

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx announces FDA Orphan Drug Designation for oxaliplatin

2026-05-28T14:40:48.000Z - 5 weeks ago

RenovoRx announces FDA Orphan Drug Designation for oxaliplatin

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026, 8:30 AM EDT - 5 weeks ago

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx announces pharmacokinetic data using TAMP platform

2026-05-26T14:34:27.000Z - 5 weeks ago

RenovoRx announces pharmacokinetic data using TAMP platform

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

May 26, 2026, 8:30 AM EDT - 5 weeks ago

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 1:40 PM EDT - 6 weeks ago

RenovoRx Transcript: A.G.P.'s Annual Virtual Healthcare Conference

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

May 19, 2026, 8:30 AM EDT - 6 weeks ago

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

2026-05-14T21:08:58.000Z - 7 weeks ago

RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

2026-05-14T21:02:36.000Z - 7 weeks ago

RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M

RenovoRx Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

RenovoRx Earnings Call Transcript: Q1 2026

RenovoRx Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

RenovoRx Earnings release: Q1 2026

RenovoRx Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

RenovoRx Quarterly report: Q1 2026

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

May 14, 2026, 4:05 PM EDT - 7 weeks ago

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RenovoRx Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 2 months ago

RenovoRx Slides: Investor presentation

RenovoRx Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

RenovoRx Proxy statement: Proxy filing

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

Apr 29, 2026, 8:30 AM EDT - 2 months ago

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Apr 23, 2026, 8:30 AM EDT - 2 months ago

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

RenovoRx files to sell 8.44M shares of common stock for holders

2026-04-16T21:15:42.000Z - 2 months ago

RenovoRx files to sell 8.44M shares of common stock for holders

RenovoRx Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

RenovoRx Registration statement: Registration filing

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Apr 14, 2026, 8:30 AM EDT - 2 months ago

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx secures Japanese patent allowance for targeted drug-delivery

2026-04-08T13:16:29.000Z - 3 months ago

RenovoRx secures Japanese patent allowance for targeted drug-delivery

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Apr 8, 2026, 8:30 AM EDT - 3 months ago

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Apr 1, 2026, 2:20 PM EDT - 3 months ago

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Earnings Call Transcript: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Earnings Call Transcript: Q4 2025

RenovoRx Annual report: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Annual report: Q4 2025

RenovoRx Earnings release: Q4 2025

Mar 30, 2026, 4:30 PM EDT - 3 months ago

RenovoRx Earnings release: Q4 2025

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 4:05 PM EDT - 3 months ago

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients

2026-03-26T13:20:11.000Z - 3 months ago

RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

Mar 26, 2026, 8:30 AM EDT - 3 months ago

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Mar 23, 2026, 8:30 AM EDT - 3 months ago

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

Mar 20, 2026, 8:30 AM EDT - 3 months ago

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

RenovoRx prices 10.6M shares at 93.8c in private placement

2026-03-18T12:45:53.000Z - 3 months ago

RenovoRx prices 10.6M shares at 93.8c in private placement

RenovoRx Announces $10 Million at Market Private Placement

Mar 18, 2026, 8:35 AM EDT - 3 months ago

RenovoRx Announces $10 Million at Market Private Placement

RenovoRx advances RenovoCath adoption at U.S. cancer centers

2026-02-27T14:01:24.000Z - 4 months ago

RenovoRx advances RenovoCath adoption at U.S. cancer centers

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Feb 27, 2026, 8:30 AM EST - 4 months ago

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx announces acceptance of clinical data abstract at 2026 SIR

2026-02-26T13:52:25.000Z - 4 months ago

RenovoRx announces acceptance of clinical data abstract at 2026 SIR

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

Feb 26, 2026, 8:30 AM EST - 4 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx establishes RenovoCath Medical Advisory Board

2026-02-10T13:47:32.000Z - 5 months ago

RenovoRx establishes RenovoCath Medical Advisory Board

RenovoRx Establishes RenovoCath® Medical Advisory Board

Feb 10, 2026, 8:30 AM EST - 5 months ago

RenovoRx Establishes RenovoCath® Medical Advisory Board

RenovoRx appoints Voll as Chief Financial Officer

2026-02-05T13:40:28.000Z - 5 months ago

RenovoRx appoints Voll as Chief Financial Officer

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Feb 5, 2026, 8:30 AM EST - 5 months ago

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx announces new clinical data on TAMP therapy platform

2026-02-04T13:36:25.000Z - 5 months ago

RenovoRx announces new clinical data on TAMP therapy platform

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

Feb 4, 2026, 8:30 AM EST - 5 months ago

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx initiated with a Buy at JonesResearch

2026-01-29T21:26:58.000Z - 5 months ago

RenovoRx initiated with a Buy at JonesResearch

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Jan 28, 2026, 8:30 AM EST - 5 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx expands RenovoCath commercial adoption to nine cancer centers

2026-01-20T13:43:26.000Z - 5 months ago

RenovoRx expands RenovoCath commercial adoption to nine cancer centers

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Jan 20, 2026, 8:30 AM EST - 5 months ago

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

Jan 14, 2026, 8:30 AM EST - 6 months ago

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial

2026-01-08T13:57:01.000Z - 6 months ago

RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

Jan 8, 2026, 8:30 AM EST - 6 months ago

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 11, 2025, 8:30 AM EST - 7 months ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx Transcript: IAccess Alpha Virtual MicroCap Conference

Dec 9, 2025, 12:30 PM EST - 7 months ago

RenovoRx Transcript: IAccess Alpha Virtual MicroCap Conference

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Dec 1, 2025, 8:30 AM EST - 7 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx Transcript: AGP Emerging AgBiotech/Bio-Solutions

Nov 20, 2025, 2:00 PM EST - 8 months ago

RenovoRx Transcript: AGP Emerging AgBiotech/Bio-Solutions

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 19, 2025, 8:30 AM EST - 8 months ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx files $50M mixed securities shelf

2025-11-14T21:40:11.000Z - 8 months ago

RenovoRx files $50M mixed securities shelf

RenovoRx price target lowered to $3 from $3.50 at Alliance Global

2025-11-14T19:20:32.000Z - 8 months ago

RenovoRx price target lowered to $3 from $3.50 at Alliance Global

RenovoRx Registration statement: Registration Filing

Nov 14, 2025, 7:00 AM EST - 8 months ago

RenovoRx Registration statement: Registration Filing

RenovoRx reports Q3 EPS (8c), two estimates (8c)

2025-11-13T21:45:48.000Z - 8 months ago

RenovoRx reports Q3 EPS (8c), two estimates (8c)

RenovoRx Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

RenovoRx Earnings Call Transcript: Q3 2025

RenovoRx Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

RenovoRx Quarterly report: Q3 2025

RenovoRx Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

RenovoRx Earnings release: Q3 2025

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 8 months ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx appoints Timothy Donahue to Strategic Advisory Board

2025-11-06T13:51:52.000Z - 8 months ago

RenovoRx appoints Timothy Donahue to Strategic Advisory Board

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 6, 2025, 8:30 AM EST - 8 months ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Nov 4, 2025, 8:30 AM EST - 8 months ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 27, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 9 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 10 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Fall Conference 2025

Sep 16, 2025, 12:30 PM EDT - 10 months ago

RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Fall Conference 2025

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 10 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 10 months ago

RenovoRx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 11 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

RenovoRx Earnings Call Transcript: Q2 2025

RenovoRx Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

RenovoRx Quarterly report: Q2 2025

RenovoRx Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

RenovoRx Earnings release: Q2 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 11 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 11 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx Transcript: Alliance Global Partners Healthcare Company Showcase

May 21, 2025, 12:40 PM EDT - 1 year ago

RenovoRx Transcript: Alliance Global Partners Healthcare Company Showcase

RenovoRx Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings Call Transcript: Q1 2025

RenovoRx Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Quarterly report: Q1 2025

RenovoRx Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

RenovoRx Earnings release: Q1 2025

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 1 year ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 1 year ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

RenovoRx Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Proxy statement: Proxy Filing

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx Transcript: LD Micro Invitational XV 2025 Conference

Apr 10, 2025, 7:00 AM EDT - 1 year ago

RenovoRx Transcript: LD Micro Invitational XV 2025 Conference

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 1 year ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Transcript: Fireside Chat

Apr 3, 2025, 12:00 PM EDT - 1 year ago

RenovoRx Transcript: Fireside Chat

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Annual report: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Annual report: Q4 2024

RenovoRx Earnings release: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

RenovoRx Earnings release: Q4 2024

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 1 year ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

iAccess_Alpha
iAccess_Alpha Jul. 2 at 3:51 PM
Missed it live? Access the $RNXT presentation replay here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
Wolfietrader
Wolfietrader Jun. 30 at 8:05 PM
$RNXT I bought 1,400 more shares. Why do I do this? Why? I like pain and mental suffering I guess
1 · Reply
Wolfietrader
Wolfietrader Jun. 30 at 3:12 PM
$RNXT so close to the Mendoza line.
1 · Reply
Wolfietrader
Wolfietrader Jun. 26 at 3:25 PM
$RNXT strange upward movement. I’m not familiar with this. Next thing you know the stock will be at $1.00. Strange days.
1 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 25 at 2:58 PM
$RNXT presentation replay now available. Access here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 24 at 4:26 PM
$RNXT wtf is that???
3 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 24 at 1:34 PM
$RNXT let’s get one hundredth of a cent gain today boys!
1 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 23 at 12:35 PM
$RNXT presents today at iAccess Alpha's Virtual Best Ideas Summer Conference. Watch live via Stocktwits or register here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 22 at 2:17 PM
$RNXT presents tomorrow at iAccess Alpha's Virtual Best Ideas Summer Conference. Watch live: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
KirkHanna
KirkHanna Jun. 17 at 6:21 PM
$RNXT Not bad price action, considering there's no catalyst next several weeks. I wonder if institutional investors have noticed it?
1 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 12 at 8:10 PM
$RNXT will present at iAccess Alpha's Virtual Best Ideas Summer Conference. June 23, 2026 | 12:30 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
1 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 10 at 1:29 PM
$RNXT wonder if we’ll regain compliance before the split
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 8 at 12:32 PM
$RNXT some crazy pre market volume today
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Jun. 4 at 12:42 AM
$RNXT let’s push on a dollar tomorrow
0 · Reply
iAccess_Alpha
iAccess_Alpha Jun. 2 at 1:07 PM
$RNXT will present at iAccess Alpha’s Virtual Best Ideas Summer Conference. June 23, 2026 | 12:30 PM ET https://www.webcaster5.com/Webcast/Page/3165/54052 #microcap #smallcap #investing
0 · Reply
Rnxtsavior
Rnxtsavior Jun. 2 at 11:27 AM
$RNXT Ok watch.. this is how well I know this paper churner.. little bump in the pre market after a higher volume day... this will sell off all day.. .80's... next .70's
1 · Reply
Rnxtsavior
Rnxtsavior Jun. 1 at 2:50 PM
$RNXT Lol.. Edward Woo.... puts this out for a little bump before the dump...who is dumping? you know.. you can say it.. everyone knows.
0 · Reply
anachartanalyst
anachartanalyst Jun. 1 at 1:02 PM
$RNXT https://anachart.com/wp-content/uploads/2026/06/1780318942_soc-img.jpg
2 · Reply
Wolfietrader
Wolfietrader May. 28 at 8:30 PM
$RNXT good volume today. I was hoping Boston Scientific was looking at investing heavily here but their stock price just hit a 52 week low.
0 · Reply
DARKP00L
DARKP00L May. 28 at 12:42 PM
$RNXT 08:41 on May. 28 2026 RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic Cancer #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher May. 28 at 12:32 PM
$RNXT RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital May. 28 at 12:00 AM
$RNXT why do we keep closing at the top of intraday? Shorts covering at end of day or is it signaling strength for the next session?
0 · Reply